Overview Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Status: Completed Trial end date: 2012-06-01 Target enrollment: Participant gender: Summary Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase: Phase 2 Details Lead Sponsor: AbbVie (prior sponsor, Abbott)Collaborator: Genentech, Inc.